SUMO2P10

Across TCGA pan-cancer cohorts, SUMO2P10 RNA is linked to patient survival in 14 of 34 cancer types, making it the most broadly survival-associated SUMO2P10 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher SUMO2P10 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated SUMO2P10 expression acts as an unfavorable survival marker, although some lineages such as LUSC and CHOL show a favorable association.

MESO, OV, and LIHC are the cancer types where SUMO2P10 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	All	0.209	0.426	.003	63	view →
OV	OS	Quartile	II,III,IV	0.782	0.887	.001	52	view →
LIHC	OS	Tertile	All	0.314	0.586	.005	24	view →
READ	DFS	Quartile	III,IV	0.478	0.826	.015	20	view →
BLCA	OS	Tertile	IV	0.233	0.607	.018	18	view →
SKCM	DFS	Tertile	II,III,IV	0.567	0.705	.016	15	view →
CESC	DFS	Quartile	III,IV	0.535	0.768	.010	14	view →
UCEC	OS	Tertile	III,IV	0.734	0.848	.015	12	view →
COAD	DFS	Tertile	II,III,IV	0.611	0.764	.004	9	view →
ACC	DFS	Tertile	IV	0.087	0.425	.020	9	view →
THYM	OS	Tertile	II,III,IV	0.869	0.973	.036	6	view →
LUSC	DFS	Quartile	II,III,IV	0.536	0.310	.010	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 14 lineages.

SUMO2P10–MESO (DFS)

Open the MESO breakdown →